Picture of Benchmark Holdings logo

BMK Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

REG - Benchmark Hlgs PLC - Notice of Q2 and Interim Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240426:nRSZ2595Ma&default-theme=true

RNS Number : 2595M  Benchmark Holdings PLC  26 April 2024

26 April 2024

 

Benchmark Holdings plc

 

("Benchmark" or "the Company")

 

Notice of Q2 and Interim Results

 

Webcast for analysts and institutional investors

Equity Development webcast for retail investors

 

Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture
biotechnology business, will announce its Q2 and interim results, for the
three and six month periods ended 31 March 2024, on Wednesday, 22 May 2024.

 

Presentation for analysts and institutional investors at 8.00 UK (9.00 CET)

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 UK time (9.00 CET).

 

The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)

 

A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/
(https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/)

 

Equity Development webcast for retail investors at 12:30pm UK time

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers at
12.30pm UK time. The webcast is open to all existing and potential
shareholders.

 

To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024
(https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024)

 

 

 For further information, please contact:
 Benchmark Holdings plc                         benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Deutsche Numis (Broker and NOMAD)              Tel:  020 7260 1000
 Freddie Barnfield, Duncan Monteith, Sher Shah

 MHP                                            Tel:  07884 494112
 Katie Hunt, Reg Hoare                          benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

 Equity Development                             Tel:  020 7065 2692

 Hannah Crowe

 

 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission
is to enable aquaculture producers to improve their sustainability and
profitability.

We bring together biology and technology to develop innovative products and
solutions which improve yield, quality and animal health and welfare for our
customers. We do this by improving the genetic make-up, health and nutrition
of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon
eggs, live feed (Artemia), specialist diets and probiotics and sea lice
treatments. Find out more at www.benchmarkplc.com
(http://www.benchmarkplc.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUNVURSUUSUAR

Recent news on Benchmark Holdings

See all news